Ftse Mib
34.160,97
1,25%
DAX
19.984,32
0,74%
S&P 500
5.970,84
-1,11%
NASDAQ
19.722,03
-1,49%
Bitcoin
93.488,72
-0,03%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Canada TSXV Arch Biopartners Inc (ARCH) Arch Biopartners Inc (ARCH) Notizie

Arch Biopartners Inc

ARCH
1,83
0,04 (2,23%)
27 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: TSX Venture
Tipo: Azione
Valuta: CAD

Ultime notizie

Data Ora Fonte Titolo
11/11/202419:46APSDosing of First Patient in a Trial for LSALT Peptide is..
11/11/202413:30GLOBEArch Biopartners Announces Dosing of First Patient in Canada..
16/10/202400:23GLOBEArch Biopartners Arranges Non-Brokered Private Placement
03/10/202413:45GLOBECloses Units for Debt Settlement
26/9/202414:46GLOBEUnits for Debt Settlement
11/9/202412:30GLOBEArch Biopartners Announces Alberta Health Services Approval..
02/8/202413:20GLOBEArch Biopartners’ Cilastatin Drug Candidate to Participate..
30/7/202422:47GLOBEArch Biopartners Closes Non-Brokered Private Placement
29/7/202422:52GLOBEArch Biopartners Arranges Non-Brokered Private Placement
27/6/202413:25GLOBEArch Biopartners Announces GMP Manufacturing of Cilastatin..
18/6/202413:35GLOBEArch Biopartners Announces University of Calgary Ethics..
16/4/202413:14GLOBESt. Michael’s Hospital Joins the Phase II Trial of LSALT..
03/4/202413:00GLOBEUHN Joins the Phase II Trial of LSALT Peptide Targeting..
02/4/202413:26GLOBEArch Biopartners Adds Three New Clinical Sites into the..
18/3/202412:28GLOBEArch Biopartners Clinical Team Publishes Data from Phase II..
15/3/202412:05GLOBEUniversity of Calgary Joins the Phase II Trial of LSALT..
07/3/202413:26GLOBEArch Biopartners Announces Dosing of First Patient in Phase..
27/2/202413:25GLOBEArch Biopartners Has Pre-IND Meeting With FDA to Discuss..
10/1/202413:26GLOBEArch Biopartners Receives Health Canada Approval to Conduct..
03/1/202413:33GLOBEArch Biopartners Receives Approval from the Turkish Ministry..
Apertura: 1,89 Min: 1,76 Max: 1,89
Chiusura: 1,79

La tua Cronologia

TSXV
ARCH
Arch Biopartners
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network